University of Jena Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Jena Free State of Thuringia Germany (1558)

Organization Overview

First Clinical Trial
2005
NCT00265434
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Center for Clinical Studies Jena | Center for Clinical Studies, Jena University Hospital | Center for Clinical Studies, University Hospital Jena | Christian Schulze | Department of Anaesthesiology and Intensive Care Medicine, Jena University Hospital | Department of Internal Medicine I, Jena University Hospital | Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital | Dr. Gerlind Schneider | Lars-Olof Muegge | Orlando Guntinas-Lichius, Prof. Dr. med. | Prof. Dr. med. Andreas Hochhaus | Universitätsklinikum Jena | University Hospital Jena, Institute of Radiology | Zentrum für Klinische Studien Jena

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Cystic Fibrosis (Phase 3)

Fibrosis (Phase 3)

Heart Failure (Phase 2)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Mouth Neoplasms (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasm, Residual (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Oropharyngeal Neoplasms (Phase 2)

Sinusitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 13